Merck’s Pneumococcal Vaccine Lands FDA Nod, Just Few Weeks After Its Rival

For the second time in five weeks, the FDA has approved a new pneumococcal conjugate vaccine, this time giving the nod to a shot from Merck & Co Inc (NYSE: MRK). The vaccine, Vaxneuvance, is designed to protect against 15 strains of pneumococcal bacteria. That’s two more strains than Prevnar 13, a product from rival Pfizer Inc (NYSE: PFE). But the total number of strains covered by Vaxneuvance is five shy of Prevnar 13’s successor, Prevnar 20, which the FDA approved in June. The clinical studies


Please enter your comment!
Please enter your name here